Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
3(37.5%)
N/A
3(37.5%)
Phase 2
1(12.5%)
Phase 4
1(12.5%)
8Total
Phase 3(3)
N/A(3)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07180277Phase 4Not Yet Recruiting

Methylprednisolone for Moderate to Severe Traumatic Brain Injury

Role: lead

NCT06778473Not ApplicableRecruiting

Intradermal Acupuncture and Self-rehabilitation Program in Patients With Severe Bell's Palsy

Role: lead

NCT06241651Not ApplicableRecruiting

CSP Versus BiVP for Heart Failure Patients with RVP Upgraded to Cardiac Resynchronization Therapy

Role: collaborator

NCT05237349Phase 2Unknown

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Role: collaborator

NCT04287660Phase 3Unknown

Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

Role: collaborator

NCT04087967Phase 3Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Role: collaborator

NCT04083911Phase 3Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

Role: collaborator

NCT02687074Not ApplicableUnknown

Effects of HFNC on Moderate and Severe Respiratory Failure Patients

Role: collaborator

All 8 trials loaded